menu
More than 85 small molecule protein degraders are currently being evaluated for the treatment
More than 85 small molecule protein degraders are currently being evaluated for the treatment
More than 85 small molecule protein degraders are currently being evaluated for the treatment

More than 85 small molecule protein degraders are currently being evaluated for the treatment

The concept of targeted protein degradationpresents revolutionary drug development opportunities and is anticipated tobring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysistargeting chimera (PROTAC), was developed about a decade ago. Presently, avariety of other such chemical entities and molecular glues are underinvestigation. In fact, certain pipeline candidates are already in the mid tolate-phase trials and are anticipated to soon enter the market.

 

To order this 330+ page report, which features 130+ figuresand 145+ tables, please visit  https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

 

The USD 3.6 billion (by 2030) financial opportunitywithin the target protein degradation market has been analyzed across thefollowing segments:

§ Type of payment oflicensing agreements

§ Upfront payments

§ Milestone payments

 

§ Type of proteindegrader

§ Degronimids

§ PROTACs

§ SARDs / SERDs

§ Specific BET and DUBinhibitors

§ Other proteindegraders

 

§ Therapeutic area

§ Neurodegenerativedisorders

§ Oncological disorders

§ Other therapeuticareas

 

§ Route ofadministration  

§ Oral

§ Intravenous

§ Other routes

 

§ Key geographicalregion

§ North America

§ Europe

§ Asia-Pacific

 

The Targeted Protein Degradation Market: Focus on Therapeuticsand Technology Platforms (based on Degronimids, ENDTACs, EpichaperomeInhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs,Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUBInhibitors), 2020-2030 report features thefollowing companies, which we identified to be key players in this domain:

§ Arvinas

§ Captor Therapeutics

§ Celgene

§ Genetech

§ Kymera Therapeutics

§ Mission Therapeutics

§ Progenra

§ Radius Health 

§  SanofiGenzyme

§  Zenopharm

 

Table of Contents

 

1. Preface


2. Executive Summary


3. Introduction

4. Current Market Landscape

5. Company Profiles

6. Clinical Trial Analysis 

7. KOL Analysis

8. Publication Analysis

9. Funding and Investment Analysis

10. Partnerships and Collaborations

11.  MarketSizing and Opportunity Analysis

12. Executive Insights

 

13. Concluding Remarks

 

14. Appendix 1: Tabulated Data

 

15. Appendix 2: List of Companies andOrganizations

 

To purchase a copy, please visithttps://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com